Advertisement

Topics

Angle PLC: Preliminary Results

20:00 EDT 27 Jul 2016 | Marketwired

GUILDFORD, UNITED KINGDOM -- (Marketwired) -- 07/28/16 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)

ANGLE plc
("ANGLE" or "the Company")

Preliminary Results for the year ended 30 April 2016

ESTABLISHED RESEARCH USE SALES AND PROGRESSED FIRST CLINICAL APPLICATION IN OVARIAN CANCER

ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, today announces audited preliminary results for the year ended 30 April 2016.

Operational Highlights

Financial Highlights

Post year end highlights

Garth Selvey, Non-Executive Chairman of ANGLE plc, commented:

"ANGLE is funded to execute our business plan with the immediate priorities of building research use sales in leading institutions, completing analytical and clinical studies to support FDA clearance in the US, and completing clinical studies for our first clinical application in ovarian cancer. The recent pilot study results in breast cancer and prostate cancer represent breakthroughs that offer major growth potential for the future. ANGLE is well positioned to become a leading player in the emerging liquid biopsy market, which is expected to revolutionise cancer care."

Details of webcast

Please see http://www.angleplc.com/investor-information/investor-centre/ for details.

For further information:

These Preliminary Results may contain forward-looking statements. These statements reflect the Board's current view, are subject to a number of material risks and uncertainties and could change in the future. Factors that could cause or contribute to such changes include, but are not limited to, the general economic climate and market conditions, as well as specific factors including the success of the Group's research and development and commercialisation strategies, the uncertainties related to regulatory clearance and the acceptance of the Group's products by customers.

Click on, or paste the following link into your web browser, to view the associated PDF document. http://www.rns-pdf.londonstockexchange.com/rns/4543F_1-2016-7-27.pdf

Contacts: RNS Customer Services 0044-207797-4400 NEXT ARTICLE

More From BioPortfolio on "Angle PLC: Preliminary Results "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...